Fig. 1From: Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agentsA summary of various MCL-targeting agents, including BTKi and other small molecular inhibitors, antibody–drug conjugates, chimeric antigen receptor T cells, bispecific antibodies, and other immune modulatorsBack to article page